Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2025-02-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024
Read more
2025-02-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024
Read more
2025-02-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024
Read more
2024-12-11 (nd.nl)
Pharming is waiting for Damrak to rise after study results - Nederlands Dagblad. The quality newspaper of Christian Netherlands
Pharming was among the risers on the Amsterdam stock exchange on Wednesday. The biotechnologist announced that he had achieved positive results with research into the effectiveness of the drug leniolisib in the treatment of children aged four to eleven years with APDS, a rare disorder of the immune system. With this data, Pharming plans to begin filing worldwide approvals for leniolisib for the treatment of pediatric patients with APDS in 2025. The share was almost 7 percent higher.
Read more
2024-10-25 (iex.nl)
AEX will probably open flat and provide a well-deserved breather in the middle of the earnings season
The American stock markets are divided, with the Nasdaq as an outlier due to super figures from Tesla. Asia also recorded mixed results, with Japan as a negative outlier in the run-up to elections. The future points to a flat (-0.06%) opening.
Read more
2024-10-25 (iex.nl)
AEX will probably open flat and provide a well-deserved breather in the middle of the earnings season
The American stock markets are divided, with the Nasdaq as an outlier due to super figures from Tesla. Asia also recorded mixed results, with Japan as a negative outlier in the run-up to elections. The future points to a flat (-0.06%) opening.
Read more
2024-10-25 (iex.nl)
AEX will probably open flat and provide a well-deserved breather in the middle of the earnings season
The American stock markets are divided, with the Nasdaq as an outlier due to super figures from Tesla. Asia also recorded mixed results, with Japan as a negative outlier in the run-up to elections. The future points to a flat (-0.06%) opening.
Read more
2024-10-25 (quotenet.nl)
Pharming boss De Vries quits after 16 years, company is heading for red figures
Sijmen de Vries will not continue as CEO of Pharming, where he found a failing company in 2008. De Vries expects Pharming to become 'gigantically profitable', but at the same time as his departure, new quarterly figures still point to red figures.
Read more
2024-10-24 (deaandeelhouder.nl)
Sijmen de Vries stops at Pharming
During the third quarter results, Pharming announced that CEO Sijmen de Vries will step down as figurehead and CEO of the company. De Vries is now 65 years old and has been active as CEO of Pharming for 16 years this week. De Vries: "I have informed the Board of Directors that, after 16 years at the helm of Pharming, I
Read more
2024-08-01 (iex.nl)
IEX closing call on Thursday, August 1, 2024
Weak US industry data is pushing shares in Amsterdam, Europe and the US deeply down. Bond investors can laugh, just like investors in the figures AMG, Fagron and Aperam.
Read more
2024-08-01 (iex.nl)
IEX closing call on Thursday, August 1, 2024
Weak US industry data is pushing shares in Amsterdam, Europe and the US deeply down. Bond investors can laugh, just like investors in the figures AMG, Fagron and Aperam.
Read more
2024-08-01 (deaandeelhouder.nl)
Pharming: Ruconest is going fast
Pharming shows strong growth in the second quarter at the ancient Ruconest. Ruconest continues to amaze; another hundred patients were added, which resulted in a 23% increase in turnover.
Read more